United Kingdom Non-Invasive Prenatal Testing Market Insights Forecasts to 2033

• The U.K. Non-Invasive Prenatal Testing Market Size was valued at USD 245 Million in 2023.
• The Market Size is Growing at a CAGR of 14.08% from 2023 to 2033
• The U.K. Non-Invasive Prenatal Testing Market Size is Expected to reach USD 915 Million by 2033

The United Kingdom Non-Invasive Prenatal Testing Market Size is anticipated to exceed USD 915 Million by 2033, Growing at a CAGR of 14.08% from 2023 to 2033.

The growing maternal age, high demand for early non-invasive prenatal testing (NIPT), rise in the prevalence of genetic disorders, and advancements in diagnostic technologies are driving the growth of the non-invasive prenatal testing market in the US.        

Market Overview

Non-invasive prenatal testing (NIPT), also known as non-invasive prenatal screening (NIPS) is used to assess the likelihood that a fetus would be born with specific genetic defects. Little DNA fragments that are circulating in a pregnant woman's blood are analyzed by this test. NIPT examines this DNA's genetic information to check for a variety of anomalies. There is no radiation involved, and the diagnostic process is safe and non-invasive. The market for non-invasive prenatal testing has grown as a result of its ability to target a broader range of pregnant women due to its safety and non-invasiveness. Prenatal testing has become more popular as a result of the introduction of cutting-edge non-invasive technologies by industry participants and their proven clinical efficacy.

Report Coverage

This research report categorizes the market for the UK non-invasive prenatal testing market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom non-invasive prenatal testing market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the UK non-invasive prenatal testing market.   

Driving Factors

Abnormal chromosomal division during pregnancy can lead to an increase in the prevalence of genetic diseases in newborns as mothers age. The rise in maternal advanced age is expected to result in greater health problems. Thus, the rise in maternal age as well as the chromosomal abnormalities surges the market demand for non-invasive prenatal testing. An increase in chromosomal abnormalities and increased product utilization in new applications drive revenue growth in the market. The advancement of current tests with enhanced chemistry, capacity, and bioinformatics analysis would also support market growth.          

Restraining Factors

The increased cost of non-invasive prenatal testing is restraining the market. Further, the lack of awareness about genetic abnormalities is hampering the market growth for non-invasive prenatal testing.

Market Segmentation

The United Kingdom Non-Invasive Prenatal Testing Market share is classified into method, application, and end user.  

• The cfDNA in maternal plasma tests segment is anticipated to grow at the fastest CAGR during the forecast period.

The United Kingdom non-invasive prenatal testing market is segmented by method into ultrasound detection, biochemical screening tests, and cfDNA in maternal plasma tests. Among these, the cfDNA in maternal plasma tests segment is anticipated to grow at the fastest CAGR during the forecast period. cfDNA is a cell-free DNA. The prenatal screening landscape has changed with the inclusion of more women and a wider spectrum of illnesses in cell-free DNA screening programs. The rising company initiatives and the advancements in technology are driving the market.

• The trisomy segment dominates the market with the largest market share during the forecast period.

The United Kingdom non-invasive prenatal testing market is segmented by application into trisomy, microdeletion syndrome, and others. Among these, the trisomy segment dominates the market with the largest market share during the forecast period. Fetal DNA found in the mother's blood is analyzed as part of NIPT, which yields important details regarding the health and any genetic disorders of the unborn child. The main purpose of this testing is to check for diseases like trisomy 18, trisomy 13, and Down syndrome (trisomy 21). The growing maternal age and prevalence of chromosomal abnormalities are driving the market growth.

• The diagnostic laboratories segment holds the largest revenue share of the UK non-invasive prenatal testing market during the forecast period.        

Based on the end user, the U.K. non-invasive prenatal testing market is divided into diagnostic laboratories and hospitals. Among these, the diagnostic laboratories segment holds the largest revenue share of the UK non-invasive prenatal testing market during the forecast period. Diagnostic laboratories are implementing initiatives to offer safe and effective prenatal tests. The increasing prevalence of chromosomal abnormalities is propelling the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.K. non-invasive prenatal testing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Illumina Inc.
• Eurofins Biomnis
• Yourgene Health
• BGI Diagnosis Co. Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2022, QIAGEN N.V. announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.  

Market Segment

This study forecasts revenue at U.K., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United Kingdom Non-Invasive Prenatal Testing Market based on the below-mentioned segments:

UK Non-Invasive Prenatal Testing Market, By Method

• Ultrasound Detection
• Biochemical Screening Tests
• cfDNA in Maternal Plasma Tests

UK Non-Invasive Prenatal Testing Market, By Application

• Trisomy
• Microdeletion Syndrome
• Others

UK Non-Invasive Prenatal Testing Market, By End User

• Diagnostic Laboratories
• Hospitals